Phase 2 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed (confirmed by tissue or cell testing) with advanced, inoperable, or metastatic squamous cell cancers in one of these areas: the lungs (SqNSCLC), head and neck including the nasopharynx (HNSCC), oesophagus (ESCC), or skin (CSCC).
- For the early dose-finding phase of the trial: people who have already tried at least one standard treatment that either stopped working or caused intolerable side effects.
- For the later phases of the trial: people who have tried no more than two lines of standard treatment that either stopped working or caused intolerable side effects.
- People who are able to provide a tissue sample for testing of a specific protein called CLDN1 at a central laboratory.
- People who are considered reasonably active and able to care for themselves, based on a standard medical scale (ECOG score of 0 or 1).
- People whose bone marrow, liver, kidneys, and other organs are functioning adequately.
- People who have recovered from side effects caused by any previous cancer treatments.
- People who have at least one tumour that can be measured using standard imaging criteria (confirm with trial site).
Who may not be able to join:
- People whose cancer is not primarily a squamous cell type — for example, those with adenosquamous carcinoma or adenocarcinoma.
- People who have received other cancer treatments too recently before the trial start date (confirm with trial site for specific timeframes).
- People whose cancer is progressing rapidly, such as with tumour bleeding or severe, uncontrolled pain from the tumour.
- People with diabetes that is not well controlled.
- People with active cancer spread to the brain or spinal cord lining.
- People with significant gastrointestinal bleeding, an active infection requiring treatment, or any other medical condition or abnormal test result that could interfere with the trial or affect safety.
- People currently taking medications known to affect the heart's electrical rhythm (QT prolongation) or that carry a risk of a serious heart rhythm problem called Torsades de Pointes.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +41782304288
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Patients with Dose Limiting Toxicities (DLTs); Number of Patients with Adverse Events; Overall Response Rate (ORR) (Phase I); Duration of Response (DoR) (Phase I); Overall Response Rate (ORR) (Phase II); Duration of Response (DoR) (Phase II)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.